Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Total Assets
Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) holds total assets worth CN¥2.98 Billion CNY (≈ $435.47 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Total Assets Trend (2014–2025)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. Also see 002940 stock market capitalisation for the company's overall valuation and market capitalisation.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets of CN¥2.98 Billion consist of 50.4% current assets and 49.7% non-current assets. Review 002940 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.3% |
| Accounts Receivable | CN¥176.03 Million | 6.0% |
| Inventory | CN¥447.47 Million | 15.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥173.68 Million | 5.9% |
| Goodwill | CN¥312.94 Million | 10.6% |
Asset Composition Trend (2014–2025)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Zhejiang Anglikang Pharmaceutical Co Ltd (002940) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's current assets represent 50.4% of total assets in 2025, a decrease from 54.9% in 2014.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2025, up from 5.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 6.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 15.2% of total assets.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.99 | 1.77 | 2.67 |
| Quick Ratio | 1.32 | 1.13 | 2.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥764.26 Million | CN¥670.57 Million | CN¥771.96 Million |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.07 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | CN¥2.95 Billion |
| Market Capitalization | $683.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.95 Billion ≈ $431.80 Million |
-0.80% |
| 2024-12-31 | CN¥2.97 Billion ≈ $435.27 Million |
-1.51% |
| 2023-12-31 | CN¥3.02 Billion ≈ $441.92 Million |
+16.33% |
| 2022-12-31 | CN¥2.60 Billion ≈ $379.89 Million |
+24.60% |
| 2021-12-31 | CN¥2.08 Billion ≈ $304.89 Million |
+7.36% |
| 2020-12-31 | CN¥1.94 Billion ≈ $283.99 Million |
+40.13% |
| 2019-12-31 | CN¥1.38 Billion ≈ $202.67 Million |
-5.80% |
| 2018-12-31 | CN¥1.47 Billion ≈ $215.14 Million |
+62.13% |
| 2017-12-31 | CN¥906.78 Million ≈ $132.69 Million |
+24.56% |
| 2016-12-31 | CN¥727.99 Million ≈ $106.53 Million |
-8.98% |
| 2015-12-31 | CN¥799.83 Million ≈ $117.04 Million |
+9.35% |
| 2014-12-31 | CN¥731.44 Million ≈ $107.03 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such … Read more